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BACKGROUND: No recent data exist on human papillomavirus (HPV) infection in Beijing, People’s Republic of China.
MATERIALS AND METHODS: We interviewed and examined a representative, randomly selected sample of 5552 sexually active women
aged 25–54 years. Cervical cell samples were analysed for HPV DNA by a MY09/11-based PCR assay.
RESULTS: Human papillomavirus prevalence was 6.7% overall and 4.8% among women without cervical abnormalities. Of the 21
subtypes identified, HPV16 was the commonest type (2.6% overall; 39.1% of HPV-positive women), followed by HPV 58 (1.0%), 33
(0.8%), 43 (0.7%) and 56 (0.7%). High-risk HPV types predominated in all age groups. Human papillomavirus prevalence was highest
in young to middle-aged women. Marital status, number of husband’s sexual partners, age at sexual debut and nulligravidity were all
associated with being HPV positive.
CONCLUSIONS: In our survey, HPV 16, HPV 58 and HPV 33 were the most prevalent HPV types in Beijing, indicating the potential for
the prophylactic HPV 16/18 vaccine in China.
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Human papillomavirus (HPV) has been established as a necessary
cause of cervical cancer, found in 99.7% of invasive cervical
carcinomas in the best-studied series (Bosch et al, 2002; Woodman
et al, 2007). Prevalence of genital HPV infections and type-specific
distribution vary greatly by geographical region (Clifford et al,
2005; de Sanjose et al, 2007). Therefore, data on HPV type-specific
prevalence among women in different populations are important
in elucidating the impact of an HPV vaccine and HPV-based
screening in those populations.
The People’s Republic of China, with a population of about 1.3
billion, is the world’s most populous country. Although Chinese
women have been considered to have a relatively low risk (LR) of
developing cervical cancer, there are approximately 100000 new
cases and 30000 deaths per year in China (Parkin et al, 2002,
2005). In Beijing, the capital of China, the population grew to 15.4
million in 2005, a robust annual increase of 2.1% (National Bureau
of Statistics of China Online, http://www.stats.gov.cn). However,
despite representing an appreciable portion of the nation’s
population, no recent data on HPV prevalence and type-specific
distribution exist for Beijing women.
In this study, we report a population-based study of the type-
specific and age-specific distribution of cervical HPV infection and
of its risk factors in Beijing, China.
MATERIALS AND METHODS
We carried out the present survey between September 2006 and
December 2008 in Beijing, which is the country’s political,
economic and cultural centre; it consists of 18 districts, four of
which are urban, four suburban and 10 outer suburban. A total of
5681 women aged 25–54 years were recruited from the population
list of four urban, four suburban and four randomly chosen outer
suburban districts in Beijing, China. On the basis of data from the
2005 census published by the National Bureau of Statistics of
China, our representative sample of the adult female population of
Beijing was stratified by age and regional distribution using a
four-stage cluster sampling method. In the first stage, 12 of the 18
districts of Beijing were randomly selected. In the second stage,
4–20 townships were randomly selected from each district
according to the proportion of each district’s population. Then in
the third stage, one neighbourhood was randomly extracted from
each township. Finally, from the lists provided by local neighbour-
hoods, we derived a final random sample of 50 women per
neighbourhood. On the basis of the age ratios of the 2005 census, we
strove to enroll approximately 10 women aged 25–34 years, 14
women aged 35–44 years, 13 women aged 45–54 years and 13
migrant women aged 25–54 years from each neighbourhood.
According to the inclusion criteria, women who (1) lived in
Beijing for more than half a year; (2) had no history of cervical
surgery; (3) were not pregnant; (4) had no history of pelvic
radiation therapy; (5) did not have a gynaecological examination
and/or treatment in the past 2 years; and (6) were physically and
mentally able to undergo an interview and a pelvic examination
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randomised sample of the population, we made house-to-house
visits to recruit these women and invite them to visit their local
Maternal and Child Health Hospitals to participate in this study.
Here, the interview was administered to the women by two–four
experienced gynaecologists, covering socio-demographic informa-
tion and obstetric and gynaecological history, including number of
sexual partners (and also of the husband); participants then had a
gynaecological examination and a cervical cell sample taken for
HPV DNA analysis.
Written consent was obtained from all participants according to
the regulations of the Beijing O&G hospital and 12 various district
Maternal and Child Health Clinics, which approved the study.
A total of 5681 women underwent a pelvic examination; a
sample of exfoliated cervical cells for liquid-based cytology and
HPV testing was collected later. First, a cytobrush was inserted into
the endocervical canal, and rotated gently in a clockwise direction
five times. A cytobrush was then inserted into the bottom of a
preservation solution vial (Thinprep, CytycCorp, Boxborough,
MA, USA) and swirled 10 times vigorously. Finally, the brush was
discarded and the vial contents were sent to Beijing O&G Hospital
for cytological analysis. All smears were reported by two cyto-
technicians separately, the abnormal/indeterminate ones were
reviewed by a senior cytologist for final diagnosis. The results were
classified according to the Bethesda System. All women with an
abnormal cytological test (ASCUS or more severe) were referred to
the study colposcopist and a biopsy was performed. All abnormal
smears and 10% of normal smears chosen at random were sent for
review by an experienced cytopathologist. Cervical biopsies were
reviewed by a senior pathologist. All confirmed or highly
suspicious high-grade or invasive lesions were treated at the
Beijing O&G Hospital with loop excision, surgical conisation,
hysterectomy or radiotherapy, according to protocols. In this
study, cervical abnormalities were defined as the presence of
histologically confirmed cervical intra-epithelial neoplasia (CIN) 1
or worse.
DNA was extracted first from the remainder of the Thinprep
sample. To confirm the presence of human DNA, b-globin PCR
analysis was performed on each sample and only b-globin-positive
samples were included in further analyses.
The overall presence of HPV DNA positivity was determined by
PCR using 50-biotinylated MY09/11 consensus primers, as
described previously (Coutlee et al, 1999). The presence of 23
subtypes, including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58,
59, 66, 68, 73, 83, MM4, 6, 11, 42, 43 and 44, was investigated by
reverse dot blot hybridisation of the PCR product, as described in
previous studies (Kawasaki and Chehab, 1994; Coutlee et al, 1999).
High-risk (HR) HPV types for this analysis included HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 (Munoz et al,
2003). All other HPV types were considered LR. Multiple HPV
infections with the presence of at least one HR type were
considered as HR.
Statistical analysis
Statistical analysis was performed using SPSS version 15 software.
Odds ratios (ORs) for HPV positivity and corresponding 95%
confidence intervals (CIs) were calculated using unconditional,
logistic regression, adjusted for age groups (25–29, 30–34, 35–39,
40–44, 45–49 and 50–54 years). The statistical significance of
trends for ORs (P for trend) was assessed by treating ordinal
variables as continuous.
RESULTS
Of the 5681 women who provided cervical cell samples, 32 had
inadequate cytology results and 97 had b-globin-negative samples,
leaving 5552 women with valid cytological and HPV results.
Among these, 268 (4.8%) had histologically confirmed cervical
abnormalities, including 210 CIN1, 37 CIN2, 18 CIN3 and 3
microinvasive carcinoma. Meanwhile, HSIL was diagnosed in
0.27% (n¼15) and the proportion of HSIL that was histologically
confirmed was 93.3%. The mean age of the total screened
population was 39.7 years.
Overall, the prevalence of HPV of any subtype was 6.7% (4.8 and
44.4% among women with normal and abnormal cervical findings,
respectively, Table 1). A total of 229 women (4.1% overall, 61.7%
of HPV-positive women) had single-type infection and a total of
142 women (2.6%, 38.3%) had multiple HPV infections. In all, 21
individual types were identified. High-risk HPV infections were
more frequent (5.8% of all women) than LR infections (2.0%). The
most commonly found types in either single or multiple infections
were HPV 16 (HR) (2.6%), HPV 58 (HR) (1.0%), HPV 33 (HR)
(0.8%), HPV 43 (0.7%) (an LR type, 41 women) and HPV 56 (HR)
(0.7%). High-risk HPV was found in 38.8% of women with cervical
abnormalities, and in only 4.1% of normal women. The proportion
of HPV 16 and HPV 18, both of which are included in currently
licensed prophylactic HPV vaccines, was 45.8% among HPV-
positive women and their prevalence was 85.7% for pathological
grades of CIN 3 or worse.
Figure 1 shows the age distribution of HPV prevalence (any
type, HR and LR types separately). Age-specific prevalence
increased from 4.9% at age 25–29 years to a peak of 8.2% at age
30–34 years and then decreased to 7.1% at age 35–39 years.
Among women aged 40–54 years, prevalence decreased progres-
sively from 7.5% at 40–44 years to 6.4 and 4.9% at ages 45–49 and
50–54 years, respectively. Age-specific prevalence in Beijing
peaked at 8.2% at 30–34 years. High-risk types were common in
women aged 30–34 years, and then gradually decreased. In
contrast, for LR prevalence, there was no significant age-specific
trend. The proportion of HPV-positive samples infected with only
one HPV type was highest at 30–34 years, whereas the proportions
with multiple types at 30–34- and 40–44-year age groups were 3.0
and 3.1%, respectively, which were higher than other age groups
(Figure 2).
Table 2 show the relationship between HPV positivity and some
major characteristics of this population after adjustment for age.
Smoking women were associated with a higher HPV prevalence
than were never smokers (OR¼1.25, 95% CI: 1.01–1.56).
Unmarried women were more likely to be infected with HR
(OR¼1.63, 95% CI: 1.07–2.49) and LR HPV (OR¼1.54, 95% CI:
0.77–3.09) than married women. Most women (96.9%) reported
having only one sexual partner in their life; those with two or
more lifetime sexual partners seemed to have an increased risk
of HR HPV positivity (OR¼1.45, 95% CI: 1.06–2.41). The
prevalence of HPV was significantly increased with the number
of husband’s sexual partners (OR for two partners vs one¼1.66,
95% CI: 1.07–2.57; OR for three partners or more vs one¼3.67,
95% CI: 0.77–17.43). The increasing age at first intercourse
was inversely associated with being HPV positive (OR for p20 vs
X28 years¼1.74, 95% CI: 1.14–2.65; OR for 21–27 vs X28
years¼1.10, 95% CI: 0.84–1.46).
Nulliparous women were more likely to be infected with HR
HPV than women who had been pregnant earlier (OR¼2.15, 95%
CI: 1.16–4.00). However, there was no association of birth
numbers with HPV positivity (data not shown). Age at first
pregnancy was unrelated to HPV infection, whereas a trend of
increased HPV positivity with younger age at first pregnancy was
seen (OR for p24 vs X30 years¼2.09, 95% CI: 1.01–4.32; OR for
25–29 vs X30 years¼2.00, 95% CI: 0.97–4.12). Oral contraceptive
use was not associated with HR and LR HPV infections, but
condom use was somewhat protective against HPV infection. No
significant association was found between HPV positivity and
race, occupation, education level, age at menarche, marriage or
menopause, or history of spontaneous or voluntary abortion (data
HPV infection in Beijing, China
R Zhao et al
1636
British Journal of Cancer (2009) 101(9), 1635–1640 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ynot show). In addition to age, when marital status, number of
sexual partners, husband’s sexual partners and smoking were
included in the same multiple logistic regression, the corresponding
ORs did not change materially.
Figure 3 shows the percentage of specific HPV types in different
pathological grades. There was an obvious increasing percentage
with increasing pathology for HPV 16 and the highest percentage
was in samples worse than CIN3. For HPV 18, the highest
prevalence was also seen in samples worse than CIN3. For HPV
types 35, 58 and 68, the highest proportion was observed in the
normal group, and for HPV types 33, 43, 56 and 66, it was observed
in the CIN1 group.
Table 1 Prevalence of various human papillomavirus (HPV) types by histological findings among 5552 women (Beijing, China, 2008)
Cervical abnormalities
Absent Present
b Total
HPV type
a Single Multiple Total (%) Single Multiple Total (%) Single Multiple Total (%)
Negative 5032 (95.2) 149 (56.0) — — 5181 (93.3)
Positive
Any 159 93 252 (4.8) 70 49 119 (44.4) 229 142 371 (6.7)
High risk 124 92 216 (4.1) 57 47 104 (38.8) 181 139 320 (5.8)
Low risk 35 43 78 (1.5) 13 20 33 (12.3) 48 63 111 (2.0)
High risk
16 51 37 88 (1.7) 30 27 57 (21.3) 81 64 145 (2.6)
58 20 22 42 (0.8) 5 7 12 (4.5) 25 29 54 (1.0)
33 6 26 32 (0.6) 2 13 15 (5.6) 8 39 47 (0.8)
56 11 18 29 (0.5) 3 7 10 (3.7) 14 25 39 (0.7)
35 6 19 25 (0.5) 0 10 10 (3.7) 6 29 35 (0.6)
18 4 12 16 (0.3) 3 6 9 (3.4) 7 18 25 (0.5)
68 8 12 20 (0.4) 2 3 5 (1.9) 10 15 25 (0.5)
31 5 8 13 (0.2) 4 6 10 (3.7) 9 14 23 (0.4)
59 4 7 11 (0.2) 2 5 7 (2.6) 6 12 18 (0.3)
51 5 3 8 (0.2) 2 2 4 (1.5) 7 5 12 (0.2)
39 2 0 2 (0.03) 3 2 5 (1.9) 5 2 7 (0.1)
45 2 2 4 (0.1) 1 1 2 (0.8) 3 3 6 (0.1)
73 0 4 4 (0.1) 0 0 0 0 4 4 (0.1)
52 0 1 1 (0.02) 0 0 0 0 1 1 (0.02)
Low risk
43 8 19 27 (0.5) 5 9 14 (5.2) 13 28 41 (0.7)
66 13 12 25 (0.5) 5 7 12 (4.5) 18 19 37 (0.7)
42 4 7 11 (0.2) 0 3 3 (1.1) 4 10 14 (0.3)
53 3 6 9 (0.2) 2 2 4 (1.5) 5 8 13 (0.2)
11 4 1 5 (0.1) 0 1 1 (0.4) 4 2 6 (0.1)
83 3 2 5 (0.1) 0 0 0 3 2 5 (0.1)
6 0 2 2 (0.03) 1 1 2 (0.8) 1 3 4 (0.1)
aThe same women can be counted more than once for multiple infection.
bIncludes all histologically confirmed CIN1 and worse.
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Figure 1 Age-specific prevalence of human papillomavirus DNA and
corresponding 95% confidence interval (Beijing, China, 2008).
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Among this representative sample of Beijing women, HPV 16 was
the most frequently detected type, as found in many previous
studies in different world regions (Clifford et al, 2005). Never-
theless, its overall prevalence was relatively low (6.7%), which
correlates with the low incidence of cervical cancer in China (Yang
et al, 2003). Meanwhile, a large proportion of women with only one
sexual partner (96.9%) in this general population was probably an
important cause of low HPV prevalence in Beijing. In previous
Asian studies, HPV prevalence was lower, such as in Vietnam
(Hanoi, 2.0%; Pham et al, 2003), Thailand (Lampang, 9.1%;
Sukvirach et al, 2003) and Indonesia (11.4%; Vet et al, 2008),
compared with countries such as Nigeria (Ibadan, 26.3%; Thomas
et al, 2004) and Chile (29.2%; Ferreccio et al, 2008).
Besides HPV 16, HR HPV 58 and 33 were also common in this
general population, followed by LR HPV 43 and HR HPV 56.
Surveys have reported relatively high HPV 58 and HPV 33
prevalence in Asia (de Sanjose et al, 2007). HPV 16, 18, 58, 33, 52
and 45 were commoner in Asia than in other areas (Bao et al,
2008b). The predominance of HPV 58 and HPV 33 in Beijing is in
accordance with the results of certain surveys in other regions of
China (Dai et al, 2006; Li et al, 2006; Bao et al, 2008a).
In our survey, HPV prevalence was highest in women aged 30–
34 years and declined thereafter. This age-specific pattern is
similar to some previous studies in China (Dai et al, 2006), but
differs somewhat from other surveys elsewhere (Munoz et al, 2004;
Hibbitts et al, 2006). In China, which is a relatively conservative
society, late marriage and late childbirth are encouraged. The
relatively late age at first intercourse (mean: 24.0 years), along with
a tendency to delay marriage and childbirth, may explain the
relatively high HPV prevalence in young to middle-aged women
in Beijing. Furthermore, persistent infections are reported to
gradually become more prominent with age (Castle et al, 2005). In
our survey, the prevalence of multiple HPV infection is high in
women aged 30–34 years. Thus, the high HPV prevalence in young
to middle-aged women in Beijing may indicate a relative lack of
viral clearance or a reactivation of latent infection, which formed
co-infection.
The number of husband’s sexual partners was strongly
associated with HPV infection, indicating the important role of
males in HPV transmission to female partners in the Beijing
population, among whom the majority (96.9%) have only one
sexual partner in their life. As expected, marital status of women
and age at first intercourse were risk factors for HPV infection.
Similar to previous studies (Deacon et al, 2000; Munoz et al, 2002;
Pham et al, 2003; Shin et al, 2003), we found that nulliparous
women had a higher prevalence of HPV than women who had been
pregnant earlier. However, there was no trend with the number of
pregnancies, as found in some studies (Thomas et al, 2004). We
found an association between smoking and HPV prevalence as in
many other (Sukvirach et al, 2003; Vaccarella et al, 2008), though
not all, studies (Harris et al, 2004). The use of oral contraceptives
was not associated with HPV infection in our study, but we had no
details of duration of use; at present, the question of an association
is unclear (Green et al, 2003). Previous findings are also
inconsistent for the association between condom use and HPV
infection (Manhart and Koutsky, 2002; Vaccarella et al, 2006); our
data indicated a possible limited protective trend.
Table 2 Detection of cervical human papillomavirus (HPV) DNA
according to major risk factors among 5552 women (Beijing, China, 2008)
HPV DNA positive
Total no. Number (%) OR
a (95% CI)
Age (years)
25–29
b 870 43 (4.9) 1
30–34 999 82 (8.2) 1.72 (1.18–2.52)
35–39 1007 71 (7.1) 1.46 (0.99–2.16)
40–44 1150 86 (7.5) 1.56 (1.07–2.27)
45–49 953 61 (6.4) 1.32 (0.88–1.97)
50–54 573 28 (4.9) 0.99 (0.61–1.61)
P for trend 0.031
Smoking
Ever 3285 238 (7.2) 1.25 (1.01–1.56)
Never
b 2266 133 (5.9) 1
Marital status
Married
b 5257 343 (6.5) 1
Unmarried
c 295 28 (9.5) 1.49 (0.99- 2.25)
Lifetime sexual partners
1
b 5378 358 (6.7) 1
X2 168 13 (7.7) 1.24 (0.64–2.04)
Husband sex partners
1
b 5270 338 (6.4) 1
2 231 24 (10.4) 1.66 (1.07–2.57)
X3 10 2 (20.0) 3.67 (0.77–17.43)
P for trend 0.021
Age at first intercourse (years)
p20 379 38 (10.0) 1.74 (1.14–2.65)
21–27 3939 261 (6.6) 1.10 (0.84–1.46)
X28
b 1226 72 (5.9) 1
P for trend 0.027
Pregnant
Never 113 12 (10.6) 1.82 (0.98–3.37)
Ever
b 5438 359 (6.6) 1
Age at first pregnancy (years)
p24 2613 182 (7.0) 2.09 (1.01–4.32)
25–29 2593 169 (6.5) 2.00 (0.97–4.12)
X30
b 227 8 (3.5) 1
P for trend 0.135
Oral contraceptives
Never
b 191 16 (8.4) 1
Ever 5361 355 (6.6) 0.75 (0.39–1.43)
Condom use
Never
b 3525 251 (7.1) 1
Ever 2027 120 (5.9) 0.8 (0.63–0.96)
Abbreviations: OR¼odds ratio; CI¼confidence interval.
aAdjusted for age.
bReference category.
cUnmarried includes separated, divorced and widowed.
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Figure 3 Human papillomavirus type-specific distribution and pathology
grade (Beijing, China, 2008).
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pathological grades, HPV 16 and HPV 18 were frequent with CIN3/
CC relative to their prevalence in normal, CIN1 and CIN2 grades,
reflecting their predominant roles in invasive carcinomas in
Beijing. In most countries, HPV 16 is by far the most common type
in cervical carcinoma, followed by HPV 18 (Bosch et al, 2008; Zhao
et al, 2008; Cai et al, 2009). It would seem that the prophylactic
vaccine against HPV 16/18 will also be effective in reducing the
cervical cancer burden in Beijing, as the prevalence of these two
types was 85.7% for pathological grades of CIN 3 or worse.
In conclusion, the commonest HPV types in the general female
population of Beijing are HPV 16, 58 and 33, and the HPV 16/18
vaccination is expected to substantially reduce the cervical cancer
burden in China.
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